CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PharmaTimes
Original article

Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb

PartnershipT-cell engagersPositive
AI Analysis

Summary

Oxford BioTherapeutics and Bristol Myers Squibb have entered into a collaboration to develop next-generation T-cell engagers for solid tumours, representing a strategic partnership in oncology therapeutics.

Importance:6/10
Sentiment:
0.60
partnershipcollaborationT-cell engagerssolid tumoursoncology
Related Companies

Read the original article

Published by PharmaTimes on April 9, 2026 12:59 PM

Read Original